Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

Idbaih, Ahmed, Canney, Michael, Belin, Lisa, Desseaux, Carole, Vignot, Alexandre, Bouchoux, Guillaume, Asquier, Nicolas, Law-Ye, Bruno, Leclercq, Delphine, Bissery, Anne, De Rycke, Yann, Trosch, Clementine, Capelle, Laurent, Sanson, Marc, Hoang-Xuan, Khe, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Mathon, Bertrand, André, Arthur, Lafon, Cyril, Chapelon, Jean-Yves, Delattre, Jean-Yves, Carpentier, Alexandre·2019·Clinical Cancer Research

Abstract

Purpose: The blood–brain barrier (BBB) limits the efficacy of drug therapies for glioblastoma (GBM). Preclinical data indicate that low-intensity pulsed ultrasound (LIPU) can transiently disrupt the BBB and increase intracerebral drug concentrations. Patients and Methods: A first-in-man, single-arm, single-center trial (NCT02253212) was initiated to investigate the transient disruption of the BBB in patients with recurrent GBM. Patients were implanted with a 1-MHz, 11.5-mm diameter cranial ultrasound device (SonoCloud-1, CarThera). The device was activated monthly to transiently disrupt the BBB before intravenous carboplatin chemotherapy. Results: Between 2014 and 2016, 21 patients were registered for the study and implanted with the SonoCloud-1; 19 patients received at least one sonication. In 65 ultrasound sessions, BBB disruption was visible on T1w MRI for 52 sonications. Treatment-related adverse events observed were transient and manageable: a transient edema at H1 and at D15. No carboplatin-related neurotoxicity was observed. Patients with no or poor BBB disruption (n = 8) visible on MRI had a median progression-free survival (PFS) of 2.73 months, and a median overall survival (OS) of 8.64 months. Patients with clear BBB disruption (n = 11) had a median PFS of 4.11 months, and a median OS of 12.94 months. Conclusions: SonoCloud-1 treatments were well tolerated and may increase the effectiveness of systemic drug therapies, such as carboplatin, in the brain without inducing neurotoxicity. See related commentary by Sonabend and Stupp, p. 3750

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3643

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 362

Metadata

Authors
Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., De Rycke, Y., Trosch, C., Capelle, L., Sanson, M., Hoang-Xuan, K., Dehais, C., Houillier, C., Laigle-Donadey, F., Mathon, B., André, A., Lafon, C., Chapelon, J.-Y., Delattre, J.-Y., & Carpentier, A.
Venue
Clinical Cancer Research
Published
2019-07-01
Volume
25
Issue
13
Pages
3793-3801
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2925110565
Cited by
362
References
34
FWCI
14.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3643
The paper
Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., De Rycke, Y., Trosch, C., Capelle, L., Sanson, M., Hoang-Xuan, K., Dehais, C., Houillier, C., Laigle-Donadey, F., Mathon, B., . . . Carpentier, A. (2019). Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3643

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.